Is NCT06173778 recruiting in Houston, TX?

Yes, NCT06173778 is currently recruiting participants at its Houston, TX location. This weight gain after quitting smoking clinical trial is actively enrolling qualified participants.

How do I join the weight gain after quitting smoking clinical trial in Houston?

To join this clinical trial in Houston, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Houston clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Weight gain after quitting smoking Clinical Trial in Houston, TX

Who Can Participate

Inclusion Criteria

Ability to provide informed consent before any study-related activity, willing to comply with al study procedures, and be available for the duration of the study.

Body mass index (BMI) ≥30 kg/m2 or ≥27 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension (unless meets medical

Exclusion Criteria

criterion 7), cardiovascular disease (unless meets medical exclusion criterion 6), dyslipidemia, or obstructive sleep apnea

Have been smoking ≥5 cigarettes per day for at least 1 year (prior to screening) and provide positive cotinine test.

Desire to quit smoking (defined as "intend to quit within one month")

Agree (if the participant is female and of child-bearing potential) to use effective contraceptive methods, unless the participant's male partner(s) is surgically sterile (underwent vasectomy).

Women of child-bearing potential must provide negative urine pregnancy tests prior to randomization.

Normal cognitive restraint (assessed as cognitive restraint score of \<4 from the Three Factor Eating Habits Questionnaire)

Have a medical history and a brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the Study Physician and the Principal Investigator Exclusion Criteria: Medical Exclusions

Personal or first-degree relative(s) history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Acute pancreatitis within the past 6 months prior to screening.

History or presence of chronic pancreatitis.

Type 1 or type 2 Diabetes Mellitus (previously diagnosed or indicated by HbA1C ≥48 mmol/mol (6.5%) as measured by central laboratory at screening).

End stage renal disease (ESRD, previously diagnosed or indicated by estimated glomerular filtration rate (eGFR) value of eGFR \< 15 ml/min/1.73 m2 as measured by central laboratory at screening).

Any of the following: myocardial infarction, stroke, hospitalization for unstable angina or transient ischemic attack within the past 60 days prior to screening.

Systolic blood pressure (SBP) \>159 mmHg and/or diastolic blood pressure (DBP) \>99 mmHg)

History of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed.

Severe gastrointestinal disease (i.e., severe gastroparesis).

Known or suspected hypersensitivity to nicotine/nicotine patches; semaglutide, excipients, or related products.

Women who are currently pregnant, or plan to become pregnant, or lactating, or of childbearing potential and are not using medically accepted forms of contraception.

Have any illness or condition which in the opinion of the Principal Investigator and/or the Study Physician would preclude safe and/or successful completion of the study. Psychiatric / Substance Use Exclusions

Psychoactive substance abuse or dependence (excluding nicotine dependence) within the past 3 months prior to screening (existing diagnosis or as determined by the structured interview).

Urine drug test positive, before randomization, for any of the following substances:

benzodiazepines

amphetamines

methamphetamine

buprenorphine

barbiturates

3,4-methylenedioxy-methamphetamine (MDMA)

Tetrahydrocannabinol (THC)

Psychotic or bipolar disorder, or mood disorder with psychotic features; or eating disorder (existing clinical diagnosis or as determined by the structured interview)

Moderate to high risk for suicidality (as determined by the structured interview). Weight-Related Exclusions

Previously undergone bariatric surgery

Gained/lost ≥4.5 kg over the past 6 months (prior to screening)

Currently enrolled in a behavioral weight management plan

Uncontrolled thyroid disease (the criterion will be assessed at the Study Physician's and the Principal Investigator's discretion) Smoking-Related Exclusions -Currently using other combustible (e.g., cigars), other (e.g., chewing tobacco, snuff, snus) or alternative (e.g., electronic cigarettes) tobacco products Medication-Related Exclusions

Currently using oral or injectable glucose lowering medications

Currently using pharmacotherapy for smoking cessation (NRT, varenicline, or bupropion)

Currently or recently (last 90 days prior to screening) taking medication used for weight management (i.e., orlistat, lorcaserin,vi naltrexone-bupropion, liraglutide, phentermine, topiramate, benzphetamine, diethylpropion, phendimetrazine)

Currently or recently (within the past 14 days prior to screening) taking medication(s) known to impact appetite and/or weight (i.e., corticosteroids, excluding inhaled) General Exclusions

Current, anticipated, or pending enrollment in another research study during this trial that could potentially affect participant safety and/or the study data/design as determined by the Principal Investigator and/or Study Physician.

Not planning to live in the area for the duration of this trial.

Surgery scheduled for the duration of the trial, except for minor surgical procedures, in opinion of the Principal Investigator and/or the Study Physician.

Unable to communicate (read, write, and speak) fluently in English.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT06173778) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Weight gain after quitting smoking Treatment Options in Houston, TX

If you're searching for weight gain after quitting smoking treatment options in Houston, TX, this clinical trial (NCT06173778) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced weight gain after quitting smoking specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all weight gain after quitting smoking clinical trials near you to find additional studies recruiting in your area.

Weight gain after quitting smoking Clinical Trial in Houston, TX

Expert Care in Houston

IRB Approved

No-Cost Care

Apply for This Houston Location

Why Participate?

Simple Process

About This Weight gain after quitting smoking Study in Houston